Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00300755 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

A Phase 3 study of Gastroesophageal Reflux, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
60
Enrollment target
20
Study locations

NCT00300755 is a Phase 3 study of Gastroesophageal Reflux that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 60 participants, below the 183-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00300755, a Phase 3 study of Gastroesophageal Reflux, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.

Conditions Studied

Gastroesophageal Reflux

Interventions

  • DRUG pantoprazole sodium enteric-coated spheroid

Study Locations (20)

Florida

  • - Gainesville
  • - Jacksonville
  • - Miami
  • - Orlando
  • - Pensacola

California

  • - Oakland
  • - Orange
  • - Sacramento
  • - San Diego

Kentucky

  • - Lexington
  • - Louisville

Massachusetts

  • - Boston
  • - Boston

Michigan

  • - Flint
  • - Southfield

Alabama

  • - Mobile

Arizona

  • - Phoenix

Delaware

  • - Wilmington

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-05
Est. Completion 2008-04
Phase Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00300755

The ClinicalTrials.gov registry entry for NCT00300755 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 25 other Gastroesophageal Reflux trials with a reported enrollment target (67% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which pantoprazole sodium enteric-coated spheroid is the first listed.

NCT00300755 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00300755 about?

NCT00300755 is a clinical study titled "Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)". To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.

What is the current status of trial NCT00300755?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2006-05. Estimated completion is 2008-04.

What conditions does trial NCT00300755 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux.

What interventions are being tested in trial NCT00300755?

The interventions under investigation include: pantoprazole sodium enteric-coated spheroid (DRUG).

Who is sponsoring clinical trial NCT00300755?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00300755 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroesophageal Reflux

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastroesophageal Reflux

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.